Mismatch Repair Deficiency clinical trials at UCSF

1 research study open to eligible people

Mismatch repair deficiency is when cells fail to correct their DNA mistakes. UCSF is conducting trials of RP1, alone and with nivolumab, to examine its effects on adult subjects. These studies are important for understanding treatment responses in people with DNA repair deficiencies.

Showing trials for

  • RP1 Monotherapy and RP1 in Combination With Nivolumab

    open to eligible people ages 18 years and up

    RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

    San Francisco, California and other locations

Our lead scientists for Mismatch Repair Deficiency research studies include .

Last updated: